Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7%

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 6,044,599 shares, an increase of 23.7% from the December 15th total of 4,887,952 shares. Approximately 10.6% of the shares of the stock are sold short. Based on an average trading volume of 1,105,707 shares, the days-to-cover ratio is currently 5.5 days. Based on an average trading volume of 1,105,707 shares, the days-to-cover ratio is currently 5.5 days. Approximately 10.6% of the shares of the stock are sold short.

Structure Therapeutics Stock Performance

NASDAQ GPCR traded up $3.62 on Monday, hitting $88.64. 1,622,313 shares of the stock were exchanged, compared to its average volume of 1,083,169. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $94.90. The firm has a market capitalization of $5.38 billion, a P/E ratio of -72.66 and a beta of -2.05. The stock has a fifty day moving average price of $55.31 and a two-hundred day moving average price of $34.24.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Sell-side analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently added to or reduced their stakes in GPCR. Balyasny Asset Management L.P. bought a new stake in shares of Structure Therapeutics during the third quarter valued at approximately $12,923,000. Pacific Heights Asset Management LLC bought a new stake in Structure Therapeutics during the 2nd quarter valued at $9,540,000. Orbimed Advisors LLC lifted its holdings in shares of Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after buying an additional 397,272 shares during the period. Paradigm Biocapital Advisors LP bought a new position in shares of Structure Therapeutics during the 3rd quarter worth $10,440,000. Finally, Casdin Capital LLC increased its stake in shares of Structure Therapeutics by 26.9% during the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after buying an additional 330,000 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent analyst reports. HC Wainwright lifted their target price on Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Stifel Nicolaus boosted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Morgan Stanley raised their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $99.11.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.